We are live on ! Find out more
ENZN

ENZON PHARMACEUTICALS INC
ENZN

Delisted

ENZN was delisted on the 19th of May, 2016.

Back to rankings

10 hedge funds and large institutions have $202K invested in ENZON PHARMACEUTICALS INC in 2016 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

75% less funds holding

Funds holding: 40 → 10 (-30)

94% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 32

97% less capital invested

Capital invested by funds: $8.07M → $202K (-$7.87M)

Holders
10
Holders Change
-30
Holders Change %
-75%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
1
Closed
32
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AA
Ancora Advisors
Ohio
+$24.8K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$4.38K
3
TCM
Tradewinds Capital Management
Washington
+$99

Top Sellers

Rank Fund Capital Flow
1
IC
Icahn Carl
Florida
-$2.77M
2
Renaissance Technologies
Renaissance Technologies
New York
-$1.48M
3
BIT
BlackRock Institutional Trust
California
-$1.33M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$706K
5
UBS Group
UBS Group
Switzerland
-$340K
Name Holding Trade Value Shares
Change 		Change in
Stake
California Public Employees Retirement System
1
California Public Employees Retirement System
California
$103K – – –
Acadian Asset Management
2
Acadian Asset Management
Massachusetts
$50K +$4.38K +8,847 +8%
AA
3
Ancora Advisors
Ohio
$20K +$24.8K +50,000 New
Tudor Investment Corp
4
Tudor Investment Corp
Connecticut
$19K – – –
OSAM
5
O'Shaughnessy Asset Management
Connecticut
$5K -$5.38K -10,850 -49%
MCM
6
Monarch Capital Management
Indiana
$4K – – –
CFA
7
CT Financial Advisors
Pennsylvania
$810 – – –
IC
8
Icahn Carl
Florida
– -$2.77M -5,904,863 Closed
Renaissance Technologies
9
Renaissance Technologies
New York
– -$1.48M -3,143,585 Closed
BIT
10
BlackRock Institutional Trust
California
– -$1.33M -2,834,816 Closed
Vanguard Group
11
Vanguard Group
Pennsylvania
– -$706K -1,503,258 Closed
UBS Group
12
UBS Group
Switzerland
– -$340K -723,072 Closed
BA
13
BlackRock Advisors
Delaware
– -$317K -673,681 Closed
Connor, Clark & Lunn Investment Management (CC&L)
14
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
– -$269K -572,321 Closed
Jacobs Levy Equity Management
15
Jacobs Levy Equity Management
New Jersey
– -$246K -523,865 Closed
Geode Capital Management
16
Geode Capital Management
Massachusetts
– -$93 -198,099 Closed
BCM
17
Bridgeway Capital Management
Texas
– -$72K -153,800 Closed
Arrowstreet Capital
18
Arrowstreet Capital
Massachusetts
– -$54K -115,380 Closed
Bank of New York Mellon
19
Bank of New York Mellon
New York
– -$49K -102,516 Closed
BIM
20
Bogle Investment Management
Massachusetts
– -$48K -102,163 Closed
CL
21
CSS LLC
Illinois
– -$44K -92,572 Closed
Northern Trust
22
Northern Trust
Illinois
– -$38K -82,058 Closed
CWM
23
Concert Wealth Management
California
– -$21K -45,939 Closed
Goldman Sachs
24
Goldman Sachs
New York
– -$14K -28,947 Closed
State Street
25
State Street
Massachusetts
– -$13K -28,090 Closed
1
2

ENZN Hedge Fund Activity: Q2 2016 in Review

10 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in ENZON PHARMACEUTICALS INC (ENZN) for Q2 2016, worth a combined $202K — down 97% from $8.07M a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of ENZN and 2 opened new positions — a net loss of 30 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was Ancora Advisors, opening a new position worth an estimated $24.8K. The largest seller was Icahn Carl, exiting entirely with an estimated $2.77M sold.

  • 10 institutional investors held ENZON PHARMACEUTICALS INC (ENZN) as of Q2 2016, down from 40 in Q1 2016.
  • Funds reported $202K of ENZON PHARMACEUTICALS INC stock for Q2 2016, down 97% quarter-over-quarter.
  • 2 funds opened new ENZON PHARMACEUTICALS INC positions in Q2 2016 and 32 closed out, a net change of -30 holders.
  • The largest ENZON PHARMACEUTICALS INC buyer in Q2 2016 was Ancora Advisors, an estimated $24.8K added.
  • The largest ENZON PHARMACEUTICALS INC seller in Q2 2016 was Icahn Carl, an estimated $2.77M sold.

Based on aggregated 13F filings for Q2 2016.